Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report: By Circulating Biomarkers, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Description

List of Tables

The global breast cancer liquid biopsy market size is expected to reach USD 2,731.02 million by 2034, according to a new study by Polaris Market Research. The report "Breast Cancer Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report - By Circulating Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), and Other Circulating Biomarkers], Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The breast cancer liquid biopsy market is experiencing significant growth due to the increasing prevalence of breast cancer globally and the rising demand for noninvasive diagnostic tools. Liquid biopsy analyzes circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood samples. It offers several advantages over traditional tissue biopsies, including reduced patient discomfort and the ability to monitor treatment response in real time. Advancements in molecular biology and genomics have improved liquid biopsy tests, enabling earlier detection and more precise treatment of breast cancer, further boosting market growth.

The rising awareness among healthcare professionals and patients regarding the benefits of early cancer detection is driving demand for liquid biopsy solutions. Government initiatives promoting cancer screening and research funding also play a crucial role in fostering market growth. In addition, the shift toward personalized medicine is leading to a greater emphasis on targeted therapies, making liquid biopsies an essential tool for tailoring treatments to individual patients based on their unique genetic profiles.

The presence of major biotechnology and pharmaceutical companies, coupled with robust research and development activities, is further stimulating innovation in this sector. As the healthcare landscape evolves and more providers adopt liquid biopsy technology, it improves breast cancer diagnosis and management while enhancing patient outcomes. All these factors mentioned above drive the breast cancer liquid biopsy market growth.

Breast Cancer Liquid Biopsy Market Report Highlights

Based on circulating biomarkers, in 2024, the circulating cell-free DNA (cfDNA) segment accounted for the largest revenue share in the breast cancer liquid biopsy market due to its enhanced sensitivity.

The early detection/screening segment, by application, is expected to register the highest CAGR during the forecast period due to the increasing awareness of the importance of early cancer diagnosis.

In 2024, North America accounted for the largest share of the breast cancer liquid biopsy market due to high adoption rates of innovative diagnostic technologies across the region.

The Asia Pacific market is expected to register the highest CAGR during the forecast period due to an increasing prevalence of breast cancer across the region.

A few global key market players are Biocept, Inc.; Epic Sciences, Inc.; F. Hoffmann - La Roche Ltd.; Fluxion Biosciences, Inc.; Myriad Genetics, Inc.; NeoGenomics Laboratories; QIAGEN; Sysmex Corporation; The Menarini Group; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the breast cancer liquid biopsy market report on the basis of circulating biomarkers, application, and region:

By Circulating Biomarkers Outlook (Revenue - USD Million, 2020-2034)

Circulating Tumor Cells (CTCs)
Circulating Cell-Free DNA (cfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers

By Application Outlook (Revenue - USD Million, 2020-2034)

Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa

Product Code: PM5160

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Breast Cancer Liquid Biopsy Market Insights

4.1. Breast Cancer Liquid Biopsy Market - Market Snapshot
4.2. Breast Cancer Liquid Biopsy Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Technological Advancements are Driving the Market Growth
  - 4.2.1.2. Rising Prevalence of Breast Cancer are Driving the Market Growth
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Development Costs
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Breast Cancer Liquid Biopsy Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
5.3. Circulating Tumor Cells (CTCs)
- 5.3.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Tumor Cells (CTCs), by Region, 2020-2034 (USD Million)
5.4. Circulating Cell-free DNA (cfDNA)
- 5.4.1. Global Breast Cancer Liquid Biopsy Market, by Circulating Cell-free DNA (cfDNA), by Region, 2020-2034 (USD Million)
5.5. Extracellular Vesicles (EVs)
- 5.5.1. Global Breast Cancer Liquid Biopsy Market, by Extracellular Vesicles (EVs), by Region, 2020-2034 (USD Million)
5.6. Other Circulating Biomarkers
- 5.6.1. Global Breast Cancer Liquid Biopsy Market, by Other Circulating Biomarkers, by Region, 2020-2034 (USD Million)

6. Global Breast Cancer Liquid Biopsy Market, by Application

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
6.3. Early Detection/Screening
- 6.3.1. Global Breast Cancer Liquid Biopsy Market, by Early Detection/Screening, by Region, 2020-2034 (USD Million)
6.4. Diagnosis
- 6.4.1. Global Breast Cancer Liquid Biopsy Market, by Diagnosis, by Region, 2020-2034 (USD Million)
6.5. Monitoring
- 6.5.1. Global Breast Cancer Liquid Biopsy Market, by Monitoring, by Region, 2020-2034 (USD Million)

7. Global Breast Cancer Liquid Biopsy Market, by Geography

7.1. Key Findings
7.2. Introduction
- 7.2.1. Breast Cancer Liquid Biopsy Market Assessment, By Geography, 2020-2034 (USD Million)
7.3. Breast Cancer Liquid Biopsy Market - North America
- 7.3.1. North America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.3.2. North America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.3.3. Breast Cancer Liquid Biopsy Market - U.S.
  - 7.3.3.1. U.S.: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.3.3.2. U.S.: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.3.4. Breast Cancer Liquid Biopsy Market - Canada
  - 7.3.4.1. Canada: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.3.4.2. Canada: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
7.4. Breast Cancer Liquid Biopsy Market - Europe
- 7.4.1. Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.4.2. Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.3. Breast Cancer Liquid Biopsy Market - UK
  - 7.4.3.1. UK: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.3.2. UK: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.4. Breast Cancer Liquid Biopsy Market - France
  - 7.4.4.1. France: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.4.2. France: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.5. Breast Cancer Liquid Biopsy Market - Germany
  - 7.4.5.1. Germany: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.5.2. Germany: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.6. Breast Cancer Liquid Biopsy Market - Italy
  - 7.4.6.1. Italy: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.6.2. Italy: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.7. Breast Cancer Liquid Biopsy Market - Spain
  - 7.4.7.1. Spain: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.7.2. Spain: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.8. Breast Cancer Liquid Biopsy Market - Netherlands
  - 7.4.8.1. Netherlands: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.8.2. Netherlands: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.9. Breast Cancer Liquid Biopsy Market - Russia
  - 7.4.9.1. Russia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.9.2. Russia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.4.10. Breast Cancer Liquid Biopsy Market - Rest of Europe
  - 7.4.10.1. Rest of Europe: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.4.10.2. Rest of Europe: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
7.5. Breast Cancer Liquid Biopsy Market - Asia Pacific
- 7.5.1. Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.5.2. Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.3. Breast Cancer Liquid Biopsy Market - China
  - 7.5.3.1. China: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.3.2. China: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.4. Breast Cancer Liquid Biopsy Market - India
  - 7.5.4.1. India: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.4.2. India: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.5. Breast Cancer Liquid Biopsy Market - Malaysia
  - 7.5.5.1. Malaysia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.5.2. Malaysia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.6. Breast Cancer Liquid Biopsy Market - Japan
  - 7.5.6.1. Japan: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.6.2. Japan: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.7. Breast Cancer Liquid Biopsy Market - Indonesia
  - 7.5.7.1. Indonesia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.7.2. Indonesia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.8. Breast Cancer Liquid Biopsy Market - South Korea
  - 7.5.8.1. South Korea: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.8.2. South Korea: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.9. Breast Cancer Liquid Biopsy Market - Australia
  - 7.5.9.1. Australia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.9.2. Australia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.5.10. Breast Cancer Liquid Biopsy Market - Rest of Asia Pacific
  - 7.5.10.1. Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.5.10.2. Rest of Asia Pacific: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
7.6. Breast Cancer Liquid Biopsy Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.6.2. Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.3. Breast Cancer Liquid Biopsy Market - Saudi Arabia
  - 7.6.3.1. Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.3.2. Saudi Arabia: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.4. Breast Cancer Liquid Biopsy Market - UAE
  - 7.6.4.1. UAE: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.4.2. UAE: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.5. Breast Cancer Liquid Biopsy Market - Israel
  - 7.6.5.1. Israel: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.5.2. Israel: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.6. Breast Cancer Liquid Biopsy Market - South Africa
  - 7.6.6.1. South Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.6.2. South Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.6.7. Breast Cancer Liquid Biopsy Market - Rest of Middle East & Africa
  - 7.6.7.1. Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.6.7.2. Rest of Middle East & Africa: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
7.7. Breast Cancer Liquid Biopsy Market - Latin America
- 7.7.1. Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
- 7.7.2. Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.7.3. Breast Cancer Liquid Biopsy Market - Mexico
  - 7.7.3.1. Mexico: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.7.3.2. Mexico: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.7.4. Breast Cancer Liquid Biopsy Market - Brazil
  - 7.7.4.1. Brazil: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.7.4.2. Brazil: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.7.5. Breast Cancer Liquid Biopsy Market - Argentina
  - 7.7.5.1. Argentina: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.7.5.2. Argentina: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)
- 7.7.6. Breast Cancer Liquid Biopsy Market - Rest of Latin America
  - 7.7.6.1. Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Circulating Biomarkers, 2020-2034 (USD Million)
  - 7.7.6.2. Rest of Latin America: Breast Cancer Liquid Biopsy Market, by Application, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. The Menarini Group
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. NeoGenomics Laboratories
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. F. Hoffmann - La Roche Ltd.
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Myriad Genetics, Inc.
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Thermo Fisher Scientific, Inc.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. QIAGEN
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Biocept, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Sysmex Corporation
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Fluxion Biosciences, Inc.
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Epic Sciences, Inc.
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development